12/09/2012 - General information
The project- based on a collaboration agreement between the Barcelona Science Park (PCB) and the companies SOM Biotech and Metasbio– will enable the discovery of new therapeutic applications of previously existing drugs (repurposing), especially in areas of great medical need and market potential, such as the central nervous system, oncology and orphan diseases.
21/06/2012 - General information
"Connect, partner and innovate". This is the slogan for the twentieth edition of the BIO International Convention, held 18 to 21 June 2012 in the city of Boston (Massachusetts, United States). BIO is the most important international business meeting in the biotechnology arena. This year, it will bring together more than 15,000 delegates from 65 countries, more than 900 exhibitors and 1,800 companies. In addition to the exhibition area, it also features a Business Forum for partnering meetings, which in 2011 generated more than 21,000 one-to-one meetings.
Més informació "GRIB participated at BIO Boston 2012, the top biotechnology convention in the world"
21/05/2012 - General information
After one week of intensive training, the closing event of the INBIOMEDvision Training Challenge successfully took place in Barcelona. This training gathered together two teams of 5 PhD students with different nationalities and scientific backgrounds (chemists, medical doctors, informatics, mathematics, biologists etc.) to work on two case studies related with health sciences during one week at the Monastery of Les Avellanes (Lleida, Spain).
27/04/2012 - Press release
Yesterday, Thursday 26 April, saw the conclusion in Barcelona of the first edition of GRIB EXPO, a symposium organised by the Research Programme on Biomedical Informatics (GRIB), a joint research group of the IMIM (Hospital del Mar Research Institute) and Pompeu Fabra University (UPF). The aim of the EXPO was to bring Biomedical Informatics closer to the clinical sector and to industrial innovation, with a view to promoting the open exchange of ideas and cooperation.
26/04/2012 - Press release
Researchers from the Research Programme on Biomedical Informatics (GRIB) from the IMIM and the Pompeu Fabra University (UPF) have identified 115 proteins via computer simulation that could be highly relevant to treat colon-rectal cancer, since they would make it possible to define the strategy to design new generation anti-cancer drugs. The study will be published in the journal PLoS ONE
Més informació "Identified 115 proteins that would allow designing new generation anti-cancer drugs"
29/02/2012 - General information
The prototype of a knowledge tool developed by the Open PHACTS Consortium has proven useful by identifying relevant information in a matter of seconds, when a traditional search could take days. It will provide information on small molecules, their pharmacological profile, pharmacokinetics, etc. from multiple sources available on the Internet.
The Carlos III Health Institute (ISCIII in Spanish) will fund, in the framework of the “International Rare Disease Research Consortium (IRDiRC)", three collaboration research projects in the whole of Spain, one of which is “DRUGS4RARE: drug repositioning for rare diseases”. This project is lead by Barcelona Science Park (PCB in Spanish), with the participation of the IMIM, together with the University of Santiago de Compostela (USC).
06/10/2011 - Press release
Certara , a US-based company and a leader in the provision of translational medicine services and solutions, is set to be the exclusive distributor of the software developed by Chemotargets the first spin-off of the IMIM (Instituto de Investigación Hospital del Mar, 'Hospital del Mar Research Institute') dedicated to the design of new drugs.
06/06/2011 - Press release
Researchers at Hospital del Mar Research Institute (IMIM) and Pompeu Fabra University (UPF) have successfully reproduced and reconstructed the complete process of a small molecule binding with its target protein. This advance enables the drug's affinity and binding level with the protein to be calculated as well as understanding the interactions established by the drug in order to act, thus moving towards safer and more efficient design of new drugs.
Més informació "A major step in molecular simulation - key to designing new drugs"
27/05/2011 - Press release
A new consortium of European organisations unite to support next generation drug discovery by providing a single view across data sources, bringing the semantic web to drug discovery.
Més informació "Semantic 'lego': an information framework to drive drug discovery."
© Institut Hospital del Mar
d'Investigacions MèdiquesLegal Notice and Privacy Policy | Cookie Policy | Site Index | Accessibility | Find Us | Contact
